You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):供港疫苗將直接於德國生產
阿思達克 01-26 08:30
復星醫藥(02196.HK)及BioNTech公布,其新型肺炎疫苗「復必泰」獲香港特別行政區食物及衛生局認可在香港作緊急使用。未來供應香港的疫苗將直接由BioNTech在德國的工廠進行生產,用於港府新型肺炎疫苗接種計劃下的供應、分發和施用等。

復星醫藥董事長兼首席執行官吳以芳表示,與BioNTech將密切配合港府的疫苗接種計劃,以確保市民早日能接種疫苗。BioNTech首席執行官兼聯合創始人Ugur Sahin表示,未來希望可儘快完成在亞洲的疫苗分配,也將繼續針對潛在的病毒變異進行疫苗測試。

公布指,根據全球第三期臨床試驗結果顯示,BioNTech的mRNA新冠疫苗已達到了所有主要療效終點,在預防新冠病毒感染方面的有效性為95%,針對65歲以上成年人的有效性超過94%,在各個年齡、性別、種族和族群人口上呈現一致的有效性。現時,該款疫苗已獲英國、美國、加拿大、歐盟等超過50個國家和地區的衛生監管部門的授權使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account